Skip to main content
Premium Trial:

Request an Annual Quote

Chemizon to Support Shenogen's Drug Programs

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – South Korean life sciences company Chemizon, a division of Optomagic, said today that it will support Shenogen Pharma Group's drug development programs aimed at developing small molecule therapeutics for cancer and endocrine disorders.

Chemizon will be responsible for a range of services and activities, including lead optimization, assay development, computational chemistry, animal pharmacology, and absorption, distribution, metabolism, and excretion processes.

Beijing's Shenogen uses the estrogen receptor ER-alpha 36 and biological assays, as well as lead compounds from traditional Chinese medicine, to develop drugs targeted at cancer stem cells.

Financial terms of the agreement were not released.

Filed under

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.